Publication Date
Spring 2026
Presentation Length
Poster/Gallery presentation
College
College of Pharmacy & Health Sciences
Department
Chemistry and Physics, Department of
Student Level
Undergraduate
Presentation Type
Talk/Oral
Summary
The mechanisms of action, pharmacokinetics, clinical efficacy, and safety of glucagon-like peptide-1 (GLP-1) receptor agonists have been evaluated for the treatment of both type 2 diabetes and obesity. The purpose of the literature review was to assess the clinical benefit and potential risk of GLP-1 receptor agonists by examining the mechanism(s) of action of drugs that utilize a variety of signaling pathways by activating receptors on specific cells. The literature reviews include: (a) Mechanistic studies of molecular signaling; (b) Pharmacokinetic analysis of the plasma concentration of drugs post-dosing; (c) Randomized controlled trials of drugs to evaluate their effectiveness; and (d) Meta-analyses of the clinical outcomes of cardiovascular and metabolic events. Gastrointestinal adverse effects continue to be the major limitations to GLP-1 receptor agonist therapy. Overall, GLP-1 receptor agonists have demonstrated a favorable risk-benefit profile in clinical practice.
Recommended Citation
Malaikham, Canna, "Evaluating the Efficacy of GLP-1 Receptor Agonists on Glycemic Control and Cardiovascular Outcomes" (2026). SPARK Symposium Presentations. 964.
https://repository.belmont.edu/spark_presentations/964
